Are Millions of Americans Getting the Wrong Cholesterol Test?

A Better Way to Measure Dangerous Cholesterol?

Every year, millions of Americans roll up their sleeves for a routine cholesterol blood test — but a groundbreaking new study suggests that many of them may be getting the wrong one. Research from Northwestern Medicine indicates that a test measuring apolipoprotein B, commonly known as apoB, may be significantly more effective than the widely used LDL cholesterol test when it comes to determining who needs more aggressive cardiovascular treatment.

The findings, published in the prestigious medical journal JAMA, could have sweeping implications for how doctors across the United States approach cholesterol management and heart disease prevention.

What Is ApoB and Why Does It Matter?

For decades, physicians have relied on LDL — often labeled "bad" cholesterol — along with non-HDL cholesterol readings to decide when a patient should begin or intensify cholesterol-lowering therapy, such as statins. While these measurements offer valuable insight, researchers argue they fall short of painting a complete picture of a person's true cardiovascular risk.

ApoB testing takes a fundamentally different approach. Rather than measuring the amount of cholesterol in the blood, it counts the actual number of harmful cholesterol-carrying particles circulating in the bloodstream. Since it is these particles — not just the cholesterol they carry — that embed themselves in artery walls and form dangerous plaques, apoB offers a more direct and accurate gauge of heart disease risk.

"Research strongly shows that apolipoprotein B is better at identifying who is at risk, because it counts the total number of harmful particles in the blood," said study lead author Ciaran Kohli-Lynch, an assistant professor of preventive medicine at Northwestern University Feinberg School of Medicine.

How the Study Was Conducted

A Large-Scale Computer Simulation

To compare the effectiveness of different cholesterol testing strategies, the research team developed a sophisticated computer model simulating 250,000 American adults who were eligible for statin therapy but had not yet been diagnosed with cardiovascular disease.

The simulation evaluated three distinct approaches to guiding cholesterol treatment — one centered on LDL levels, one on non-HDL cholesterol, and one on apoB. In each scenario, when patients failed to meet their designated target, treatment was escalated, first by switching to more potent statins and then by adding the medication ezetimibe if necessary.

Researchers tracked each strategy across a patient's lifetime, measuring outcomes that included heart attacks, strokes, overall life expectancy, quality of life, and total healthcare costs.

ApoB Came Out on Top

Across every meaningful measure, the apoB-guided strategy outperformed the other two approaches. It prevented more cardiovascular events, improved health outcomes, and — critically — did so in a way that remained cost-effective for the U.S. healthcare system.

"We found that apoB testing to intensify cholesterol-lowering medication would prevent more heart attacks and strokes than current practice, and that these health benefits were achieved at a cost that represents good value for U.S. healthcare payers," Kohli-Lynch stated.

The researcher also noted that this marks the first comprehensive analysis to confirm that apoB-guided treatment is not only clinically superior but also economically viable.

Why ApoB Isn't Already Standard Practice

Despite mounting evidence supporting apoB as a superior cardiovascular risk marker, it remains largely absent from routine clinical care. One major barrier is practicality — apoB typically requires an additional blood draw beyond the standard cholesterol panel, adding both cost and inconvenience for patients and healthcare providers alike.

The central question driving this research was straightforward: Is the added expense of apoB testing justified by the clinical benefits it delivers? Based on the study's findings, the answer appears to be a resounding yes.

Rising Stakes in Cholesterol Management

The timing of this research is particularly significant. Earlier this year, the American Heart Association, joined by ten other leading medical organizations, released updated guidelines recommending that many individuals begin cholesterol-lowering therapy at younger ages than previously advised.

As more people become eligible for treatment, and as a growing arsenal of cholesterol-lowering medications becomes available, the need to accurately identify who will benefit most from intensive therapy has never been greater.

"This means it is increasingly important to accurately identify who would benefit most from intensive treatment," Kohli-Lynch emphasized.

Heart disease remains the number one cause of death in the United States, accounting for enormous human and financial costs. If apoB testing were to become a standard part of cardiovascular risk assessment, experts believe it could meaningfully shift those numbers — saving lives while delivering measurable value to the broader healthcare system.

The study, formally titled "Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy," was supported by an American Heart Association Career Development Award. Additional Northwestern University co-authors included Drs. John Wikins and Samuel Luebbe.